|Videos|November 25, 2022
CAR T-Cell Therapy in Multiple Myeloma Treatment
Dr Patel continues the conversation of novel treatments with an examination of CAR T-cell therapies in multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Full results from the phase 3 CERVINO trial assessing etentamig in relapsed/refractory multiple myeloma will be shared at the 23rd IMS Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
3
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
4
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
5